USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Cambridge Biotech Corp.ora- Ti
Address:
365 Plantation Street
Worcester, MA 01605
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $107,230.00 3
SBIR Phase II $945,084.00 2

Award List:

PURIFICATION OF HTLV-I RECOMBINANT ENVELOPE ANTIGEN

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

PURIFICATION OF HTLV-I RECOMBINANT ENVELOPE ANTIGEN

Award Year / Program / Phase:
1989 / SBIR / Phase II
Award Amount:
$429,624.00
Agency:
HHS
Principal Investigator:
Abstract:
The long term objective of the research initiated by this proposal is to develop an improved diagnostic assay for detection of antibodies to htlv-i in human sera using recombinant dna derived antigens. htlv-i is a human retrovirus that has been shown to cause a form of adult t-cell leukemia, and has… More

RECOMBINANT SUBUNIT VACCINE FOR HUMAN CYTOMEGALOVIRUS

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$7,230.00
Agency:
HHS
Principal Investigator:
Kensil, Charlotte A , Principal Investigator
Abstract:
The long-term objective of this project is the development of an effective vaccine against human cytomegalovirus (cmv). to accomplish this, experimental formulations containing a unique and safe purified saponin adjuvant will be compared to control preparations in saline, in freund's complete… More

RAPID DIAGNOSTIC FOR CLOSTRIDIUM DIFFICILE TOXIN B

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Coughlin, Richard T , Principal Investigator
Abstract:
N/a

RAPID DIAGNOSTIC FOR CLOSTRIDIUM DIFFICILE TOXIN B

Award Year / Program / Phase:
1994 / SBIR / Phase II
Award Amount:
$515,460.00
Agency:
HHS
Principal Investigator:
Coughlin, Richard T , Principal Investigator
Abstract:
The long-term objective is to develop a rapid enzyme linked immunoassay for toxigenic clostridium difficile. c. difficile is the most frequent cause of antibiotic-associated diarrhea and colitis, and the most frequently identified cause of enteric disease in industrialized nations. single treatment… More